Notably, PSAT1-mediated cancer-derived EVs promote osteoclast differentiation and accelerate bone metastasis, highlighting this pathway as a potential therapeutic target for inhibiting metastatic progression, supported by in vitro and in vivo models [108]. The gene discussed is PSAT1; the disease is cancer.